Pharsight

Farxiga patents expiration

FARXIGA's oppositions filed in EPO

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(1 year, 3 months from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6936590 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US9198925 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Oct, 2020

(3 years ago)

US9238076 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(2 months ago)

US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(9 months from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(9 months from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(1 year, 14 days from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(2 years from now)

US8906851 ASTRAZENECA AB Method for treating diabetes
Aug, 2026

(2 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(3 years from now)

US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8221786 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US7851502 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Aug, 2028

(4 years from now)

US8721615 ASTRAZENECA AB Ampoule comprising an ampoule holder
Jan, 2030

(5 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
May, 2030

(5 years from now)

US11826376 ASTRAZENECA AB Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same
Jul, 2039

(15 years from now)

US11903955 ASTRAZENECA AB Methods of treating heart failure with reduced ejection fraction
Mar, 2040

(15 years from now)

US10973836 ASTRAZENECA AB Methods of treating heart failure with reduced ejection fraction
Mar, 2040

(15 years from now)

Farxiga is owned by Astrazeneca Ab.

Farxiga contains Dapagliflozin.

Farxiga has a total of 21 drug patents out of which 4 drug patents have expired.

Expired drug patents of Farxiga are:

  • US6936590
  • US9198925
  • US9238076
  • US6414126

Farxiga was authorised for market use on 08 January, 2014.

Farxiga is available in tablet;oral dosage forms.

Farxiga can be used as reducing fasting plasma glucose in a human in need thereof in combination with a sustained-release composition containing exendin-4, treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone, reduce the risk of cardiovascular death and worsening heart failure in adults with heart failure with reduced ejection fraction, without type ii diabetes, and having an hba1c of < 5.7%, reduce the risk of cardiovascular death and hospitalization for heart failure and urgent heart failure visits in adults with heart failure with preserved ejection fraction and without type ii diabetes, treatment of type 2 diabetes mellitus, treatment of type 2 diabetes mellitus in combination with exenatide, reduction of the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction and without type ii diabetes.

Drug patent challenges can be filed against Farxiga from 08 January, 2018.

The generics of Farxiga are possible to be released after 09 March, 2040.

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-857) Apr 30, 2024
M(M-298) May 08, 2026
M(M-238) Feb 22, 2022
New Indication(I-834) May 05, 2023
M(M-212) Oct 20, 2020
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-157) Mar 11, 2018
New Indication(I-841) Oct 18, 2022

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using DAPAGLIFLOZIN ingredient

NCE-1 date:

08 January, 2018

Market Authorisation Date:

08 January, 2014

Treatment:

Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in combination with exenatide; Reducing fasting plasma glucose in a human in need thereof in combination with a sustained-r...

Dosage:

TABLET;ORAL

How can I launch a generic of FARXIGA before its drug patent expiration?

More Information on Dosage

FARXIGA family patents

Family Patents